NCT07845422 A Study of Music Therapy for Anxiety in People With Cancer
| NCT ID | NCT07845422 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2026-09-04 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2026-09-04 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are doing this study to compare two different music-based treatment approaches and see if one may work better to reduce anxiety. The researchers will also study whether these music-based treatment approaches help people feel socially connected and change how they cope with anxiety, and whether these changes are linked to lower anxiety levels. Both approaches use music-based activities to treat anxiety. One of the approaches uses an artificial intelligence (AI)-powered song creation platform to write songs with a music therapist. The other approach involves music listening exercises and music-based discussions with research staff, during which you will learn about music culture and history.
Eligibility Criteria
Criteria: * Patients must have a pathologically confirmed advanced cancer diagnosis: stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or leukemia * Currently receiving oncological treatment * Age ≥ 18; English speaking * Ambulatory as indicated by a Karnofsky performance score of 60 or higher * Score of 8 or higher on the Hospital Anxiety and Depression Scale (HADS) anxiety subscale * Anxiety symptoms lasting for at least 1 month * Greater than 6-month expected survival as judged by the treating oncologist or clinician on the study team * No diagnosis of bipolar disorder, schizophrenia, or substance abuse * Score of 10 or lower on Blessed Orientation-Memory-Concentration * No prior receipt of music therapy within the past six months * Not currently receiving any form of psychotherapy * Concomitant Medications * No initiation or change in scheduled anxiety medications (e.g., anxiolytics, sedatives, hypnotics, antidepressants) within the past 4 weeks * Initiation or change in PRN anxiety medications are allowed within the past 4 weeks * No plan to initiate or change scheduled anxiety medications during the study * Initiation or change in PRN anxiety medications are allowed during the study * Access to an internet-connected device * Able to provide informed consent * Willing to adhere to study procedures, including randomization, session attendance, and completion of assessments
Contact & Investigator
Kevin Liou, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07845422 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07845422 currently recruiting?
Yes, NCT07845422 is actively recruiting participants. Contact the research team at liouk@mskcc.org for enrollment information.
Where is the NCT07845422 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07845422 clinical trial?
NCT07845422 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Kevin Liou, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.